Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myeloid, Acute 4Lymphoma 3Graft vs Host Disease 3Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Biphenotypic, Acute 2Hematologic Neoplasms 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Anemia, Refractory 1

Interventions

fludarabine phosphate 25Peripheral Blood Stem Cell Transplantation 24Cyclophosphamide 22Whole-Body Irradiation 18Mycophenolic Acid 16Cyclosporine 15Tacrolimus 12Busulfan 12Etoposide 11Antilymphocyte Serum 11Methotrexate 9Melphalan 9Bortezomib 9Rituximab 8Filgrastim 8Carboplatin 7Therapeutics 6Lenalidomide 6Everolimus 6Doxorubicin 6Vorinostat 5Radiotherapy 5Prednisone 5Flow Cytometry 5Alemtuzumab 5tanespimycin 4Vincristine 4Sirolimus 4Psychiatric Rehabilitation 4Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoblastic Lymphadenopathy × Abatacept × Other hematologic neoplasm × Clear all
NCT07388563 2026-05-08

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Suspended
20 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡